CN107613987A - The topical spray composition of momestasone furoate - Google Patents
The topical spray composition of momestasone furoate Download PDFInfo
- Publication number
- CN107613987A CN107613987A CN201680029218.7A CN201680029218A CN107613987A CN 107613987 A CN107613987 A CN 107613987A CN 201680029218 A CN201680029218 A CN 201680029218A CN 107613987 A CN107613987 A CN 107613987A
- Authority
- CN
- China
- Prior art keywords
- composition
- topical spray
- spray composition
- aqueous
- mixture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to the stabilization of the spray form of momestasone furoate, quick-drying non-aqueous topical composition, said composition includes one or more solubilizer, one or more non-aqueous volatile solvents and film forming agent or softening agent.The method for preparing said composition is also provided.The invention further relates to application of the momestasone furoate topical spray composition in treatment psoriasis, atopic dermatitis (atopic eczema) and other dermatologic disorders and disease.
Description
Technical field
The present invention relates to the quick-drying non-aqueous topical spray composite of momestasone furoate, also provides and prepares these combinations
The method of thing.
Background technology
Topical corticosteroid is a kind of with anti-inflammatory, antipruritic and vasoconstrictor effects compound.Their usual quilts
For alleviating flush, hydroderma (swelling), itch, crusting, come off, chap, ooze out, psoriasis, atopic dermatitis (idiocrasy
Eczema) and other skin diseases, such as contact dermatitis, seborrhea, eczema, dermatitis herpetiformis, neurodermatitis or
Autoeczematization.
Momestasone furoate is the synthesis corticosteroid for having anti-inflammatory activity.The chemical name of momestasone furoate is 9 α, 21- bis-
Chloro- 11 β, pregnant-Isosorbide-5-Nitrae-diene -3, the 20- diketone 17- (2- furoates) of the Alpha-Methyl of 17- dihydroxy -16, its empirical formula are
C27H30Cl2O6, molecular weight 521.4, and there is following structural formula:
Momestasone furoate is white-cream coloured powder, and it is practically insoluble in water, is slightly soluble in octanol, in be dissolved in ethanol.
Momestasone furoate can be commercially available with various topical formulations, such as emulsifiable paste, ointment and washing lotion.Its withCommercially sold for brand name, and suitable for alleviating corticosteroid responsiveness skin 2 years old or more older
Scorching inflammatory and pruritis.
US4775529 discloses the topical lotions composition of the corticosteroid included in the water alcohol matrix containing propane diols.
US4808610 is disclosed comprising momestasone furoate, hexylene glycol, water, Chinese wax, albolene (white
Petrolatum) and other compositions topical cream composition.
EP1886686 (B1) discloses to be selected from comprising momestasone furoate, water and at least one aromatic alcohol and at least one
Two different combinations of solvent organized and the local medicine composition for the other additives being optionally present.Said composition includes
Solution, microemulsion, gel, washing lotion, emulsifiable paste or ointment.
EP2575822 (A2) discloses the local medicine composition for including momestasone furoate, hexylene glycol, water and oil phase.Should
Composition is preferably moulded as cream.
The preparation of emulsifiable paste of many comprising topical corticosteroid and ointment is greasy, and is therefore being coated to big
It is not pleasant when on areas of skin.In addition, some conventional emulsifiable pastes and ointment bases are excitant for skin
, when especially generation effect usually requires to contact for a long time, and the fluidity of washing lotion causes physics coating to be difficult to control
On desired area.Several commercially available topical formulations mainly can not provide in demand subtract to infected region
The effect of hypopathia pain, illness and other dermatologic disorders especially for such as psoriasis.These preparations will not improve patient
Compliance.Therefore it is usually preferred to spray composite, it can increase the ease for use of patient.
WO2000045795 discloses topical pharmaceutical's spray composite, and it is included in the one or more in volatile vehicle
Medicine and one or more film forming polymers.When being sprayed on local location, said composition formed it is stable, can exhale
The film of suction, and the medicine can be obtained by the film is transdermal.
WO2011026076 (A2) discloses no propellant, sprayable topical composition, its include steroidal compounds,
Emulsifying agent, polymer, water, water-immiscible material and penetration enhancers.
However, conventional topical spray preparation can only retain the shorter time on spraying position.For example, their easy quilts
Erasing, it is therefore desirable to frequent repetitive administration.In addition, some topical spray compositions often stimulate skin, and need after application
The longer time is wanted to dry.Furthermore some spray agents can not provide uniform, thin closure film after spray coating, and this for
It is desirable to treat psoriasis, to maintain the hydration of skin.Therefore, for can effectively treat such as psoriasis and idiocrasy
The dermatologic disorders of dermatitis simultaneously can improve the topical spray composition of patient's compliance and still suffer from unsatisfied demand.
When attempting to develop the new non-aqueous topical spray composite of momestasone furoate, the present inventor is in surprise
It was found that use one or more solubilizer, one or more non-aqueous volatile solvents and one or more film forming agents or softening agent
Formed composition is stable, there is provided closure film, there is provided longer action time, there is more preferable patient's compliance, and
Show the effect suitable with commercially available momestasone furoate composition in the market.The composition of the present invention can applied
Rapid draing after on skin.These compositions can effectively treat psoriasis, atopic dermatitis (atopic eczema) with
And other dermatologic disorders or disease.
The content of the invention
This specification is related to quick-drying non-aqueous topical spray composite of momestasone furoate and preparation method thereof.
In one aspect, this specification is related to quick-drying non-aqueous topical spray composite, and it is included:
(i) momestasone furoate,
(ii) one or more solubilizer, and
(iii) one or more non-aqueous volatile solvents.
In another aspect, this specification is related to quick-drying non-aqueous topical spray composite, and it is included:
(i) momestasone furoate,
(ii) one or more solubilizer,
(iii) one or more non-aqueous volatile solvents, and
(iv) one or more film forming agents.
In another aspect, this specification is related to quick-drying non-aqueous topical spray composite, and it is included:
(i) momestasone furoate,
(ii) hexylene glycol,
(iii) one or more non-aqueous volatile solvents, and
(iv) one or more film forming agents.
In another aspect, this specification is related to quick-drying non-aqueous topical spray composite, and it is included:
(i) momestasone furoate,
(ii) one or more solubilizer,
(iii) one or more non-aqueous volatile solvents,
(iv) one or more softening agents, and
(v) one or more acidulants.
In another aspect, this specification is related to quick-drying non-aqueous topical spray composite, and it is included:
(i) momestasone furoate,
(ii) one or more solubilizer, and
(iii) one or more non-aqueous volatile solvents;
Wherein said composition forms stable closure film.
In another aspect, this specification is related to quick-drying non-aqueous topical spray composite, and it is included:
(i) 0.01% to 1% (w/w) momestasone furoate,
(ii) 1% to 15% (w/w) one or more solubilizer, and
(iii) 75% to 95% (w/w) one or more non-aqueous volatile solvents.
In another aspect, this specification is related to quick-drying non-aqueous topical spray composite, and it is included:
(i) 0.01% to 1% (w/w) momestasone furoate,
(ii) 1% to 15% (w/w) hexylene glycol,
(iii) 75% to 95% (w/w) one or more non-aqueous volatile solvents, and
(iv) 1% to 10% (w/w) one or more film forming agents.
In another aspect, this specification is related to quick-drying non-aqueous topical spray composite, and it is included:
(i) 0.01% to 1% (w/w) momestasone furoate,
(ii) 1% to 15% (w/w) hexylene glycol,
(iii) 75% to 95% (w/w) one or more non-aqueous volatile solvents,
(iv) one or more softening agents, and
(v) one or more acidulants.
In another aspect, this specification provides the quick-drying non-aqueous topical spraying combination of the stabilization of momestasone furoate
Thing.
In another aspect, the quick-drying non-aqueous topical spray composite that this specification is related to momestasone furoate is being controlled
Application in treatment psoriasis, atopic dermatitis (atopic eczema) and other dermatologic disorders or disease.
Brief description
Fig. 1:Of the invention (embodiment 2) with it is commercially availablePharmacokinetics between ointment
Comparative study.
Specific embodiment
This specification is related to quick-drying topical spray composition of momestasone furoate and preparation method thereof.
In one aspect, this specification is related to quick-drying non-aqueous topical spray composite, and it is included:
(i) momestasone furoate,
(ii) one or more solubilizer, and
(iii) one or more non-aqueous volatile solvents.
In another aspect, this specification is related to quick-drying non-aqueous topical spray composite, and it is included:
(i) momestasone furoate,
(ii) one or more solubilizer,
(iii) one or more non-aqueous volatile solvents, and
(iv) one or more film forming agents.
In another aspect, this specification is related to quick-drying non-aqueous topical spray composite, and it is included:
(i) momestasone furoate,
(ii) hexylene glycol,
(iii) one or more non-aqueous volatile solvents, and
(iv) one or more film forming agents.
In another aspect, this specification is related to quick-drying non-aqueous topical spray composite, and it is included:
(i) momestasone furoate,
(ii) one or more solubilizer,
(iii) one or more non-aqueous volatile solvents,
(iv) one or more softening agents, and
(v) one or more acidulants.
In another aspect, this specification is related to quick-drying non-aqueous topical spray composite, and it is included:
(i) momestasone furoate,
(ii) one or more solubilizer, and
(iii) one or more non-aqueous volatile solvents;
Wherein said composition forms stable closure film.
In another aspect, this specification is related to quick-drying non-aqueous topical spray composite, and it is included:
(i) 0.01% to 1% (w/w) momestasone furoate,
(ii) 1% to 15% (w/w) one or more solubilizer, and
(iii) 75% to 95% (w/w) one or more non-aqueous volatile solvents.
In another aspect, this specification is related to quick-drying non-aqueous topical spray composite, and it is included:
(i) 0.01% to 1% (w/w) momestasone furoate,
(ii) 1% to 15% (w/w) hexylene glycol,
(iii) 75% to 95% (w/w) one or more non-aqueous volatile solvents, and
(iv) 1% to 10% (w/w) of one or more film forming agents.
In another aspect, this specification is related to quick-drying non-aqueous topical spray composite, and it is included:
(i) 0.01% to 1% (w/w) momestasone furoate,
(ii) 1% to 15% (w/w) hexylene glycol,
(iii) 75% to 95% (w/w) one or more non-aqueous volatile solvents,
(iv) one or more softening agents, and
(v) one or more acidulants.
Rapid draing after term " rapid draing " as used herein refers to the composition on skin is applied to.Properly
Ground, the drying time of the topical spray composition are less than 10 minutes, preferably shorter than 5 minutes, such as less than 2 minutes.
Term "non-aqueous" as used herein refers to that the composition is substantially anhydrous.In the present invention, " the composition
It is substantially anhydrous " mean:Said composition is anhydrous, or, if said composition is aqueous, water content is very low
's.In the present invention, if aqueous, water content is the 5% or lower, preferably 3% or lower of composition weight, more preferably
2% or lower, and more preferably 1% or lower, even more preferably 0.5%.
Term " Mometasone " as used herein includes Mometasone or its any pharmaceutically acceptable salt or ester or derivative, example
Such as momestasone furoate.In the composition usage amount of momestasone furoate for composition total weight 0.01% to 5% (w/w),
0.01% to 1% (w/w), such as 0.1% (w/w).
Term " solubilizer " as used herein refers to the component for contributing to momestasone furoate to dissolve.Suitable solubilizer includes oneself
Glycol, propane diols, polyethylene glycol or its mixture.Preferable solubilizer includes hexylene glycol.Solubilizer makes in the composition
Dosage is 1% to 20% (w/w) of composition total weight, such as 3% (w/w), 5% (w/w).
Term " solvent " as used herein refers to the composition for contributing to medicine to dissolve in the formulation.The solvent is substantially usual
It is volatile.One of advantage comprising volatile solvent or volatile vehicle is that it promotes the composition rapid draing.Close
Suitable volatile solvent can be selected from nonaqueous solvents.Volatile nonaqueous solvents may be selected from ethanol, ethyl acetate, isopropanol,
Acetone, Ethyl formate, methyl acetate, methyl ethyl ketone, cyclomethicone (cyclomethicone), dimethiconol
(dimethiconol), hexamethyldisiloxane or its mixture.The usage amount of solvent is composition total weight in the composition
50% to 99% (w/w), such as more than 70%, 75% or 80%.
The topical spray composition of this specification can further include cosolvent.Specifically, the addition of the cosolvent
Improve dissolving of the momestasone furoate in the volatile solvent.Suitable cosolvent includes benzoic acid alkyl base ester, benzylalcohol, palm
Sour isopropyl esters, isopropyl myristate, adipic acid diisopropyl ester, TC, 1-METHYLPYRROLIDONE
Or its mixture.The usage amount of cosolvent is 1% to 20% (w/w) of composition total weight in the composition, such as 3%
(w/w), 5% (w/w).
Term " film forming agent " as used herein refers to the material for providing smooth, uniform thin closure film after the solvent evaporates.Should
Film is firmly adhered on skin and thus, it is possible to retain the suitable period on skin.The film forming agent includes but is not limited to
Acrylate copolymer or copolymer, including methacrylate polymer and copolymer, such as methyl methacrylate and methyl-prop
Olefin(e) acid butyl ester non-ionic copolymer (B), dimethylaminomethyl ethyl acrylate and neutral methacrylic acid esters
Copolymer (E100), Type B ammonio methacrylate copolymer (RS), A types ammonium methacrylate is total to
PolymersRL), A types methacrylic acid copolymer (LI00), Type B methacrylic acid copolymer (S100), acrylate/octylacrylamidoUrethane polymer is common
Polymers, polyvinyl acetate, polyvinyl alcohol, PVP, alkylated polyvinyl pyrrolidone, vinyl pyrrolidone-acetic acid second
Alkene ester (VA), cellulose acetate, hydroxypropyl methyl cellulose, Hydroxypropyl ethyl cellulose, hydroxyethyl cellulose,
Methylcellulose, ethyl cellulose or its mixture.The usage amount of film forming agent is the 1% of composition total weight in the composition
To 15% (w/w), 1% to 10% (w/w), 1% to 5% (w/w), such as 2% (w/w), 5% (w/w).
Term " softening agent " as used herein refers to the material of softening or submissive skin.Softening agent be used to correct skin
Dry, Scaling, and closure barrier is also provided.Suitable softening agent includes such as stearyl alcohol, glycerin mono-fatty acid ester, glycerine list
Ricinoleate, glyceryl monostearate, cetanol, isopropyl isostearate, stearic acid, isobutyl palmitate, different whale
Ceryl alcohol stearate, oleyl alcohol, isopropyl laurate, lauric acid hexyl ester, decyl oleate, octadecane -2- alcohol, different cetanol, whale
It is ceryl alcohol palmitate, dimethyl polysiloxane, decanedioic acid di-n-butyl ester, isopropyl myristate, stearic acid isopropyl esters, hard
Resin acid butyl ester, polyethylene glycol, triethylene glycol, lanolin, sesame oil, coconut oil, peanut oil, castor oil, acetylated lanolin
Alcohol, oil, mineral oil, butyl myristate, isostearic acid, palmitic acid, linoleic acid isopropyl esters, Lauryl lactate, lactic acid meat
Cardamom ester, decyl oleate, myristyl myristate and their mixture.The usage amount of softening agent in the composition
For 1% to 20% (w/w), 1% to 10% (w/w), 5% to 15% (w/w) of composition total weight, for example, 5% (w/w) or
10% (w/w).
The topical spray composition of this specification can include acidulant.Various available acidulants include but is not limited to lemon
Acid, anhydrous citric acid, citric acid monohydrate, DL-LACTIC ACID, DL-malic acid, DL- tartaric acid, fumaric acid, L MALIC ACID, L- wine
Stone acid, salicylic acid, glycolic (glycol acid), acid potassium tartrate, potassium citrate, DL- potassium hydrogen tartrates, potassium gluconate,
Sodium lactate, L-TARTARIC ACID sodium, sodium citrate, ascorbic acid and their mixture.
The topical spray composition of this specification can include one or more antioxidant.The antioxidant may be selected from DL-
Alpha- tocopherols, BHT (BHT), fourth hydroxyanisol (BHA), ascorbyl palmitate, no ascorbic acid, food
Sub- propyl propionate or its mixture.The usage amount of antioxidant is 0.01 to about 0.5% (w/ of composition total weight in the composition
Such as 0.07% (w/w) or 0.09% (w/w) w),.
The topical spray composition of this specification can include the added ingredient for improving the composition.These compositions include increasing
Mould agent, surfactant, penetration enhancers, wetting agent, colouring agent, chelating agent.The example of these compositions is this area many institute's weeks
Know.
The topical spray composition of this specification can be prepared by any suitable conventional method.For example, the part
Spray composite can be by preparing including following method and step:Momestasone furoate is dissolved in solubilizer, then by institute
Mixture is obtained to be added in one or more non-aqueous volatile solvents.Then, sequentially add the film forming agent, softening agent, its
Its excipient, it is then sufficiently mixed until forming settled solution.
The topical spray composition of this specification can be applied on skin by using spray dispensing devices.Described point
Fixed or variable dosing can be provided with device to apply, such as energy storage dosing pump (stored-energy
Metered dose pump) or manual metered dose pump.
The topical spray composition of this specification can form stable closure film on skin after the drying.The closure film is
Water-fast, and it will not easily be washed off, but retain longer time on skin.After use, the film can lead to
Cross and wiped and be easily removed with tampon.
The topical spray composition of this specification can be used for treatment or prevention psoriasis or atopic dermatitis, and (idiocrasy is wet
Rash) and other dermatologic disorders and disease.
The psoriasis can be chronic plate-like psoriasis or palm toe psoriasis.
The topical spray composition of this specification experienced the Journal of Sex Research steady in a long-term of acceleration.
This specification will obtain more detailed description by following non-limiting examples.
Embodiment
Embodiment 1
Method:
1. momestasone furoate is dissolved in hexylene glycol, the mixture is then added to isopropyl myristate and second
In the mixture of alcohol.
2. Type B ammonio methacrylate copolymer and A types ammonio methacrylate copolymer are added to obtained in step 1
In solution, and it is stirred well to and forms settled solution.
Embodiment 2
Method:
1. momestasone furoate is dissolved in hexylene glycol, the mixture is then added to isopropanol and myristic acid isopropyl
In the mixture of base ester.
2. acrylate/octylacrylamido and vinylpyrrolidone/vinyl acetate copolymer are added
To in step 1 in obtained solution, and be stirred well to and to form settled solution.
3. said mixture is added slowly to dimethiconol-hexamethyldisiloxane carrier solvent under agitation
In, and further be stirred well to form settled solution.
Embodiment 3
Method:
1. momestasone furoate is dissolved in hexylene glycol, the mixture is then added to isopropanol and myristic acid isopropyl
In the mixture of base ester.
2. by glycerin mono-fatty acid ester and citric acid added in obtained solution, being then sufficiently stirred in step 1 until
Form settled solution.
Embodiment 4
Method:
Momestasone furoate is dissolved in hexylene glycol, the mixture is then added to isopropyl myristate, diethyl
In the mixture of glycol list ethylether and ethanol.Vinylpyrrolidone/vinyl acetate copolymer is finally added, and it is fully mixed
Close until forming settled solution.
Embodiment 5
Method:
Momestasone furoate is dissolved in hexylene glycol, then by the mixture added to isopropyl myristate, the third two
In the mixture of alcohol and ethanol.Acrylate copolymer is finally added, and is sufficiently mixed until forming settled solution.
Embodiment 6:
Method:
1. momestasone furoate is dissolved in hexylene glycol, the mixture is then added to isopropanol and myristic acid isopropyl
In the mixture of base ester.
2. acrylate/octylacrylamido and vinylpyrrolidone/vinyl acetate copolymer are added
To in obtained solution, be then sufficiently stirred in step 1 until formed settled solution.Then lemon is added in the mixture
Acid is simultaneously sufficiently stirred.
3. slowly cyclomethicone is added in said mixture under agitation, then it is sufficiently stirred until forming clarification
Solution.
Stability study
The stability of the topical spray composition of this specification is assessed by following acceleration for stabilization Journal of Sex Research.According to reality
Apply the formula of example 3 and 6 and method prepares two kinds of compositions, and these compositions are carried out surely under the conditions of various temperature and humidities
Qualitative research.It was found that these compositions are stable under acceleration conditions.Table 2 shows result of study data.
Table 2:
Assess in vivo:
The stability and effect of the topical spray composition of this specification pass through dermatology stability assessment and rat skin
Pharmacokinetics research are assessed.
I, dermatology stability assessment:
The dermatology stability of the composition prepared according to embodiment 2 and 3 is in double blinding, nothing in toe psoriatic is slapped
Assessed in control, multicenter study.Include 30 patients's (including 19 males and 11 are women) altogether, the age exists
Between 18-65 year, all suffered from two palms slightly to the psoriasis of moderate.At about 10-15cm distance by described in
Composition is equably sprayed on each palm 3-4 times.The security of these compositions is passed through in T0, product by dermatologist
The clear and definite clinical sign on two palms (is seen by dermatologist when T, product are applied rear T+15 to 20 minutes immediately after
Examine) and function sign (by patient perceptions and reporting to dermatologist) marking assess.Table 1 represents the physics of spray composite
Characteristic, and table 2 represents the research evaluation scheme and the observation result of dermatologist.The composition is within 2-3 minutes
Dry and form smooth uniform films.The clinical sign and functive is not observed when product is using rear 15-20 minutes
Sign has increase relative to baseline (T0).
Table 1:
Table 2:
II, rat skin Pharmacokinetics research:
0.1% momestasone furoate topical spray composition is prepared according to embodiment 2.Said composition is sprayed on male rat
Skin on.For the rat of another group, in an identical manner and the concentration similar with the spray composite coats city
The 0.1% momestasone furoate topical ointment product sold --Ointment.After application 2 hours and 8 hours when receive
Collect rat skin, and the amount of Mometasone is measured in the skin of two groups.Pharmacokinetics analysis shows, it is flat in skin
Equal Mometasone concentration exceedes commercially available in the spray composite prepared according to embodiment 2Ointment (figure
1)。
Claims (16)
1. quick-drying non-aqueous topical spray composite, it is included:
(i) momestasone furoate,
(ii) one or more solubilizer,
(iii) one or more non-aqueous volatile solvents, and
(iv) one or more film forming agents.
2. topical spray composition as claimed in claim 1, wherein the solubilizer is the one or more in following:
Hexylene glycol, propane diols, polyethylene glycol or its mixture.
3. topical spray composition as claimed in claim 2, wherein the solubilizer is hexylene glycol.
4. topical spray composition as claimed in claim 1, wherein the non-aqueous volatile solvent is one in following
Kind is a variety of:Ethanol, ethyl acetate, isopropanol, acetone, Ethyl formate, methyl acetate, methyl ethyl ketone, cyclomethicone, poly- two
Methylsiloxane alcohol, hexamethyldisiloxane or its mixture.
5. topical spray composition as claimed in claim 1, wherein the film forming agent is selected from:Methyl methacrylate and methyl
The copolymer of butyl acrylate, the copolymer of dimethylaminomethyl ethyl acrylate and neutral methacrylic acid esters, Type B methyl-prop
Olefin(e) acid ammonium copolymer, A types ammonio methacrylate copolymer, A types methacrylic acid copolymer, Type B methacrylic acid copolymer, third
Olefin(e) acid ester/octylacrylamido, urethane polymer or copolymer, polyvinyl acetate, polyvinyl alcohol, poly- dimension
Ketone, alkylated polyvinyl pyrrolidone, vinylpyrrolidone/vinyl acetate, cellulose acetate, hydroxypropyl methyl fiber
Element, Hydroxypropyl ethyl cellulose, hydroxyethyl cellulose, methylcellulose, ethyl cellulose or its mixture.
6. topical spray composition as claimed in claim 1, wherein the composition is further included selected from following common molten
Agent:Benzoic acid alkyl base ester, benzylalcohol, isopropyl myristate, isopropyl myristate, adipic acid diisopropyl ester, diethyl two
Alcohol list ethylether, 1-METHYLPYRROLIDONE or its mixture.
7. topical spray composition as claimed in claim 1, wherein said composition further include acidulant.
8. topical spray composition as claimed in claim 1, wherein said composition form stable closure film.
9. topical spray composition as claimed in claim 1, it is included:
(i) 0.01% to 1% (w/w) momestasone furoate,
(ii) 1% to 15% (w/w) hexylene glycol,
(iii) 75% to 95% (w/w) one or more non-aqueous volatile solvents, and
(iv) 1% to 10% (w/w) one or more film forming agents.
10. quick-drying non-aqueous topical spray composite, it is included:
(i) momestasone furoate,
(ii) one or more solubilizer,
(iii) one or more non-aqueous volatile solvents,
(iv) one or more softening agents, and
(v) one or more acidulants;
Wherein said composition forms stable closure film.
11. topical spray composition as claimed in claim 9, wherein the solubilizer is one kind or more in following
Kind:Hexylene glycol, propane diols, polyethylene glycol or its mixture.
12. topical spray composition as claimed in claim 10, wherein the solubilizer is hexylene glycol.
13. topical spray composition as claimed in claim 9, wherein the non-aqueous volatile solvent is one in following
Kind is a variety of:Ethanol, ethyl acetate, isopropanol, acetone, Ethyl formate, methyl acetate, methyl ethyl ketone, cyclomethicone, poly- two
Methylsiloxane alcohol, hexamethyldisiloxane or its mixture.
14. topical spray composition as claimed in claim 9, wherein said composition are further included selected from following common molten
Agent:Benzoic acid alkyl base ester, benzylalcohol, isopropyl myristate, isopropyl myristate, adipic acid diisopropyl ester, diethyl two
Alcohol list ethylether, 1-METHYLPYRROLIDONE or its mixture.
15. topical spray composition as claimed in claim 9, wherein said composition form stable closure film.
16. topical spray composition as claimed in claim 9, it is included:
(i) 0.01% to 1% (w/w) momestasone furoate,
(ii) 1% to 15% (w/w) hexylene glycol,
(iii) 75% to 95% (w/w) one or more non-aqueous volatile solvents,
(iv) one or more softening agents, and
(v) one or more acidulants.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN1670/CHE/2015 | 2015-03-31 | ||
IN1670CH2015 | 2015-03-31 | ||
PCT/IB2016/051827 WO2016157112A1 (en) | 2015-03-31 | 2016-03-31 | Topical spray compositions of mometasone furoate |
Publications (1)
Publication Number | Publication Date |
---|---|
CN107613987A true CN107613987A (en) | 2018-01-19 |
Family
ID=57005771
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201680029218.7A Pending CN107613987A (en) | 2015-03-31 | 2016-03-31 | The topical spray composition of momestasone furoate |
Country Status (3)
Country | Link |
---|---|
CN (1) | CN107613987A (en) |
EA (1) | EA201792173A1 (en) |
WO (1) | WO2016157112A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019224035A1 (en) * | 2018-05-24 | 2019-11-28 | Almirall, S.A. | Topical pharmaceutical compositions comprising a corticosteroid |
EP4108234A1 (en) * | 2021-06-25 | 2022-12-28 | RaDes GmbH | Topical pharmaceutical formulation |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000045795A2 (en) * | 1999-02-05 | 2000-08-10 | Cipla Limited | Topical sprays comprising a film forming composition |
CN1198563C (en) * | 1998-03-31 | 2005-04-27 | 强生消费者公司 | Acidified composition for topical treatment of nail and skin conditions |
WO2011026076A2 (en) * | 2009-08-31 | 2011-03-03 | Dr. Reddy's Laboratories Ltd. | Topical formulations comprising a steroid |
-
2016
- 2016-03-31 CN CN201680029218.7A patent/CN107613987A/en active Pending
- 2016-03-31 WO PCT/IB2016/051827 patent/WO2016157112A1/en active Application Filing
- 2016-03-31 EA EA201792173A patent/EA201792173A1/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1198563C (en) * | 1998-03-31 | 2005-04-27 | 强生消费者公司 | Acidified composition for topical treatment of nail and skin conditions |
WO2000045795A2 (en) * | 1999-02-05 | 2000-08-10 | Cipla Limited | Topical sprays comprising a film forming composition |
WO2011026076A2 (en) * | 2009-08-31 | 2011-03-03 | Dr. Reddy's Laboratories Ltd. | Topical formulations comprising a steroid |
Also Published As
Publication number | Publication date |
---|---|
EA201792173A1 (en) | 2018-04-30 |
WO2016157112A1 (en) | 2016-10-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4603164B2 (en) | Moose composition | |
CN107666902B (en) | Topical pharmaceutical composition | |
JP6793715B2 (en) | Tetracycline skin pharmaceutical composition | |
JP5529539B2 (en) | Pharmaceutical composition | |
AU2013285409B2 (en) | A topical composition comprising a film-forming polymer for delivering an active ingredient to skin | |
US20090069364A1 (en) | Pharmaceutical compositions of 5-alpha-reductase inhibitors and methods of use thereof | |
JP4227677B2 (en) | Film-forming antifungal composition | |
US7387788B1 (en) | Pharmaceutical compositions of nicotine and methods of use thereof | |
JP2005314323A (en) | Hair growth formulation | |
US20110207765A1 (en) | Topical composition comprising a combination of at least two penetration enhancing agents | |
CN105769836A (en) | Composition for skin improvement comprising hexamidines and retinoids | |
US10391121B2 (en) | Magnesium chloride composition for dermatological use | |
KR100861978B1 (en) | Cosmetic compositon containing azelaic acid for treating acne skin and its manufacturing method thereof | |
CN116715574A (en) | Azelaic acid liquid salt and preparation method and application thereof | |
CN107613987A (en) | The topical spray composition of momestasone furoate | |
WO2008012071A2 (en) | Pharmaceutical compositions of nicotine and methods of use thereof | |
JP2007509122A (en) | Transdermal pharmaceutical spray formulation comprising a VP / VA copolymer and a non-aqueous vehicle | |
WO2023187116A1 (en) | Mirabegron formulation | |
CA3040867C (en) | Halobetasol propionate compositions | |
EP4285931A1 (en) | Composition for external application | |
JP2002533383A (en) | Spray-type cosmetic composition and matrix used in the composition for application to the skin | |
TW201729802A (en) | Liquid external preparation | |
TWI544924B (en) | Transdermal preparation | |
WO2007086582A1 (en) | OIL-IN-WATER TYPE EMULSION LOTION CONTAINING 22-OXA-1α,25-DIHYDROXYVITAMIN D3 AND METHOD OF TREATING SKIN DISEASE BY USING THE SAME | |
JP7262227B2 (en) | film-forming agent for external use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20180119 |
|
WD01 | Invention patent application deemed withdrawn after publication |